Sandoz announced that its products Wyost® and Jubbonti®, both containing denosumab-bbdz, have been approved by the US FDA.

Clotrimazole, a diminutive molecule of pharmacological relevance, exerts its influence as an astoundingly powerful CYP51A1 inhibitor.

Innate Pharma SA has declared that its pioneering research on the preclinical compound IPH45, a unique Antibody Drug Conjugate that targets Nectin-4 by inhibiting topoisomerase I.

AbbVie, a US-based pharma company, partnered with French firm OSE Immunotherapeutics on Feb 28 to co-develop OSE-230, a new monoclonal antibody for chronic inflammation.

LAVA has reported progress in clinical phase achievements by Pfizer with the drug PF-08046052, previously known as SGN-EGFRd2 or LAVA-1223.

Estradiol (E2), a predominant female sex hormone and a member of the estrogen family, is responsible for regulating the menstrual and estrous cycles.

Inborn Therapeutics: Initial Participant Treated in Early-to-Mid Stage Trial of IPH6501 for Recurrent or Resistant B-Cell Non-Hodgkin Lymphoma.

Sulfamethoxazole was first approved in 1965 by FDA , it was first marketed by Roche and sold under the trade name Gantanol® in the US.

CASI Pharma Announces Encouraging Early Results for BI-1206 in Managing Persistent Forms of Non-Hodgkin’s Lymphoma in Chinese Study.

Remdesivir,also known by its trade name VEKLURY®,is a RNA-dependent RNA polymerase (RdRp) inhibitor developed by Gilead Sciences.

Nektar Therapeutics has launched a Phase 2b trial to assess Rezpegaldesleukin in individuals with severe forms of Alopecia Areata.

Paracetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain.